Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HONIG JONATHAN has filed a new 13G, reporting 9.51% ownership in $APPY - https://fintel.io/i/honig-jonathan and https://fintel.io/i/honig-jonathan
Well, I'll say this. If they can afford to not only pay him that amount of money. But also give him a large amount of stock in the company. They must be going to make good money for the next two years!!
IS ANYBODY GOING TO STOP THESE THIEVES AND SCUMBAGS LUNDY AND MCGONEGAL!!!!!!!!
THE SEC NEEDS TO INVESTIGATE THIS TRANSACTION
Current Report Filing (8-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 21, 2016
Venaxis, Inc.
( Exact name of Registrant as specified in its charter)
Colorado
001-33675
84-155337
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
1585 South Perry Street
Castle Rock, Colorado
80104
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(303) 794-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously announced by Venaxis, Inc., a Colorado corporation (the "Company"), in May 2015 the Compensation Committee (the "Committee") of the Board of Directors (the "Board"), and the Board, approved a retention program for Stephen Lundy and Jeffrey McGonegal, the Company's named executive officers. The Compensation Committee and the Board, in approving such retention program, focused on the importance of and need to retain the services of such named executive officers in pursuing alternative corporate transactions for the Company. Such retention program included a retention bonus, equal to 50% of base salary to be paid to each such named executive officer in connection with the consummation of a corporate transaction . On September 21, 2016, following the closing of the acquisition of BiOptix Diagnostics, Inc., the Compensation Committee and the Board approved payment of the retention bonuses. The aggregate retention bonuses approved equaled $327,265.
Also on September 21, 2016, the Board determined that Richard J. Whitcomb, the Company's Senior Vice President, Corporate Development was an executive officer of the Company. Mr. Whitcomb was the former chief executive officer of BiOptix Diagnostics, Inc., prior to its acquisition by the Company on September 12, 2016. On September 15, 2016, the Company entered into an offer letter of employment with Mr. Whitcomb, providing him with a new hire bonus of $25,000, base salary of $245,000 per year, eligibility to participate in the Company's incentive bonus plan and equity incentive plan, and a new hire stock option grant to acquire 35,000 shares of the Company's common stock with a two-year vesting period, an exercise price equal to the closing price on the date of grant and a ten-year term. The stock option grant was made outside of the Company's 2002 Stock Incentive Plan, as amended, as a new hire award. Under the offer letter, Mr. Whitcomb is entitled to receive certain severance benefits if his employment is terminated by the Company without cause.
The foregoing description of Mr. Whitcomb's employment arrangement is a summary only. The offer letter is attached to this Form 8-K as an exhibit and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed herewith:
Exhibit No.
Document
10.1
Offer Letter, dated September 15, 2016, to Richard J. Whitcomb.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Venaxis, Inc.
By:
/s/ Jeffrey McGonegal
Name:
Jeffrey McGonegal
Title:
Chief Financial Officer
Date: September 27, 2016
EXHIBIT INDEX
Exhibit No.
Document
10.1
Offer Letter, dated September 15, 2016, to Richard J. Whitcomb.
$APPY end of the day volume and pps rising? Something coming?
Would love to see this back below $3
Big ask slaps followed by small bid whacks. What gives
I wouldn't be surprised to see Barry, Ladd, or $MGT add more here at $APPY. Something big is coming imo
$4 & $4.4 break could bring $5's quickly imo on this low ss play
$APPY o/s 3,876,690 Between barry, $MGT, & Ladd they own 580,964 14.98%. What is $APPY & $MGT up to????
Ok so just 2 of many trades made by $MGT & Ladd are big.
40,640 @ $4.12/sh = $167,436.80
27,860 @ $3.71/sh = $103,360.60
Total= 68,500 $270,797.40
So ask your self that is just 2 trades out of many purchases from Ladd & $MGT. Why are they investing so heavily into $APPY. I have no clue but it makes me even more bullish on $APPY
I meant 40,640 shares @ $4.12 = $167,436
$40,640 buy @ $4.12 from Ladd or $MGT on the 17th. They bought in big into $APPY for some reason
Dont know but 3.90 resistance about to break
$APPY what's up with all these 100 share trades? Computer trades?
$APPY come on and break that $4
$3.25 x $4.10 (0 volume) pre market info
Bid now $3.21. Slowly creeping up
$3x$4.10 pre market. No volume yet.
Has anyone figured out why $MGT took a 5% ownership position with $APPY. Looks like Barry also increased his position to almost 10% combined almost 15% ownership
$11.32(200ma) on the weekly chart $APPY
$3.84/sh final trade in after hours. Can't wait to see how tomorrow plays out
We traded around 55% of the O/S today
Call me crazy but I am still holding my entire position here. Was able to get a nice average die to the decline all day. Still on the red though with this but imo $MGT panic that was created today carried over to this. Both had a short attack. Waiting for the dust to settle. Just glad I have shares already because with tiny ss stocks once they take off its hard to get shares. Just my opinion. Good luck to all that's here
* * $APPY Video Chart 05-18-16 Pump-and-Dump * *
Link to Video - click here to watch the technical chart video
There is a reason Ladd and $MGT took a 5% stake here. $APPY might have gotten short attacked today but there has to be a bigger picture here imo
All it takes is some nice buying pressure to send this back up easily
Yup, bio-tech are very volatile and especially low floaters like this one.
I've seen some of these bad boys run up to 50 bucks in the day
Charts awesome.. Bios rock that's for sure..
Well it's just the tail end of lunch time ...
Exactly! Right now it sucks but once this short raid on $APPY slows down back up we go imo
This can sky rocket any time
$APPY: 3.8M O/S.....18.4M ASSETS, 1.7M LIABILITIES AND MK CAP ONLY APPROX. 13M
and BIG BALLZZZ....lots of volatility...
Small ss plays require strong stomachs
Dropped $2.25/sh off the high of the day
Gap closed!!!! Let's go Bulls
$5.10 no guts no glory!!!!!!!
At $10/sh the market cap would still be less than $40mill!!! $APPY baby
Peeps getting word that $MGT is involved!!! $APPY could go nuts
$5.5 broke!!! Let's get this to $10's today
Still early yet. Lots of people haven't even seen that $MGT is involved here
Followers
|
68
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2109
|
Created
|
08/29/07
|
Type
|
Free
|
Moderators |
http://www.aspenbiopharma.com/
http://finance.yahoo.com/q/h?s=APPY
http://moneycentral.msn.com/ownership?Holding=5%25+Ownership&Symbol=APPY
AspenBio Pharma, Inc. (APPY) is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products that have large worldwide market potential. We were originally formed in August 2000, as a Colorado corporation to produce purified proteins for diagnostic applications and have successfully leveraged our foundational science and technology expertise to rapidly develop a pipeline of new products. Today, the Company is primarily focused on advancing towards commercialization, our recently patented blood-based human diagnostic test, AppyScore™ to aid in the diagnosis of human appendicitis and several novel reproduction drugs for use in high value animals.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |